Ezetimibe plus simvastatin cardiovascular outcomes study program

Expert Rev Cardiovasc Ther. 2008 Jan;6(1):17-25. doi: 10.1586/14779072.6.1.17.

Abstract

Ezetimibe is a drug that impairs intestinal cholesterol absorption and decreases blood cholesterol levels. It has been shown that added to statins it can achieve a further reduction of low-density lipoprotein-cholesterol of 18-20%, overcoming the increase in absorption that follow the reduction in cholesterol synthesis by statins. Four major outcome trials are underway to study the effect of ezetimibe plus simvastatin in different subsets of high-risk patients: familiar hypercholesterolemia, degenerative aortic stenosis, chronic kidney disease and acute coronary syndrome. Hopefully, in the next few years the information provided by these trials will allow us to further reduce the increasing burden of cardiovascular disease.

Publication types

  • Review

MeSH terms

  • Acute Coronary Syndrome / drug therapy*
  • Acute Coronary Syndrome / epidemiology
  • Acute Coronary Syndrome / prevention & control
  • Anticholesteremic Agents / administration & dosage
  • Anticholesteremic Agents / therapeutic use*
  • Aortic Valve Stenosis / drug therapy*
  • Atherosclerosis / prevention & control
  • Azetidines / administration & dosage
  • Azetidines / therapeutic use*
  • Disease Progression
  • Drug Therapy, Combination
  • Ezetimibe
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Hyperlipoproteinemia Type II / drug therapy*
  • Kidney Failure, Chronic / drug therapy*
  • Kidney Failure, Chronic / epidemiology
  • Simvastatin / administration & dosage
  • Simvastatin / therapeutic use*
  • Treatment Outcome

Substances

  • Anticholesteremic Agents
  • Azetidines
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Simvastatin
  • Ezetimibe